Pacira BioSciences Inc PCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
-
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
-
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
-
Pacira BioSciences Reports Second Quarter 2024 Financial Results
-
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
-
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Trading Information
- Previous Close Price
- $15.89
- Day Range
- $15.90–16.63
- 52-Week Range
- $11.16–35.95
- Bid/Ask
- $16.51 / $17.01
- Market Cap
- $761.79 Mil
- Volume/Avg
- 669,680 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 5.29
- Price/Sales
- 1.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 712
- Website
- https://www.pacira.com
Comparables
Valuation
|
Metric
|
PCRX
|
LTP
|
AMPH
|
|---|---|---|---|
Price/Earnings (Normalized) | 5.29 | — | 11.65 |
Price/Book Value | 0.87 | 89.84 | 3.21 |
Price/Sales | 1.30 | — | 3.47 |
Price/Cash Flow | 4.20 | — | 10.16 |
Price/Earnings
PCRX
LTP
AMPH
Financial Strength
|
Metric
|
PCRX
|
LTP
|
AMPH
|
|---|---|---|---|
Quick Ratio | 5.49 | 18.70 | 2.55 |
Current Ratio | 6.82 | 19.23 | 3.52 |
Interest Coverage | 8.62 | — | 5.80 |
Quick Ratio
PCRX
LTP
AMPH
Profitability
|
Metric
|
PCRX
|
LTP
|
AMPH
|
|---|---|---|---|
Return on Assets (Normalized) | 6.12% | — | 14.18% |
Return on Equity (Normalized) | 11.26% | — | 33.14% |
Return on Invested Capital (Normalized) | 6.44% | — | 18.97% |
Return on Assets
PCRX
LTP
AMPH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Dygvqfnhxd | Fndw | $86.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Bnvfsdnxh | Hljbj | $74.3 Bil | |||
| Haleon PLC ADR
HLN
| Cgvtvscp | Gztt | $45.9 Bil | |||
| Viatris Inc
VTRS
| Qlhlhcn | Xcpg | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Cjqpjsykz | Wdjkg | $13.2 Bil | |||
| Catalent Inc
CTLT
| Jynltrt | Yhdck | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Fxdbfhhq | Rgxcsjf | $3.4 Bil | |||
| Perrigo Co PLC
PRGO
| Gjqnyvsd | Lnbd | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Qrhzsbvwv | Rpds | $2.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Mwznrhk | Yzrp | $2.2 Bil |
United States